|
Market Closed -
London S.E.
12:35:05 2026-10-30 pm EDT
|
5-day change | 1st Jan Change | ||
| 82.50 GBX | -.--% |
|
-.--% | +2.48% |
| Oct. 15 | Arecor Therapeutics Obtains Patents in Europe, US, India, for Rapid-acting Insulin | MT |
| Oct. 15 | Arecor Therapeutics Plc Strengthens Patent Protection For Its Proprietary AT278 Product | CI |
| Market Cap | 37.37M 50.07M 44.84M 41.25M 69.86M 4.75B 71.17M 492M 197M 2.5B 188M 184M 7.89B | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 31.81M 42.61M 38.16M 35.1M 59.45M 4.05B 60.57M 419M 168M 2.13B 160M 157M 6.71B | EV / Sales 2026 * |
106x | EV / Sales 2027 * | 181x |
| Free-Float |
55.19% | Yield 2026 * |
-
| Yield 2027 * | - |
London S.E.GBX
| Markets | Quality | ||
|---|---|---|---|
London S.E.
| AREC | Delayed | |
Deutsche Boerse AG
| 6UI | Delayed | |
|
Börse Stuttgart
| 6UI | Delayed |
Last Transcript: Arecor Therapeutics plc
| 1 month | +13.79% | ||
| 3 months | +35.25% | ||
| 6 months | +25.00% | ||
| Current year | +2.48% |
| 1 week | 81.25 |  | 85 |
| 1 month | 70 | | 86 |
| Current year | 55.27 | | 95 |
| 1 year | 55.27 | | 95 |
| 3 years | 35.4 | | 199 |
| 5 years | 35.4 | | 449 |
| 10 years | 35.4 | | 472 |
| Manager | Title | Age | Since |
|---|---|---|---|
Sarah Howell
CEO | Chief Executive Officer | 51 | 2021-04-12 |
David J. Ellam
DFI | Director of Finance/CFO | - | 2024-11-17 |
Jan Jezek
CTO | Chief Tech/Sci/R&D Officer | - | 2007-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Sarah Howell
BRD | Director/Board Member | 51 | 2021-04-12 |
Mohammad Fazeli
BRD | Director/Board Member | 61 | 2017-08-31 |
Andrew Richards
CHM | Chairman | 66 | 2021-04-12 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 5/20/26 | Free | Chief Executive Officer | 160,000 | 0.4238% | ||
| 5/20/26 | Free | Executive/Senior Manager | 95,000 | 0.2516% | ||
| 5/20/26 | Free | Chief Financial Officer | 105,000 | 0.2781% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | +15.38% | -56.58% | 50.07M | |
| -0.62% | -1.87% | +42.87% | +64.15% | 63.77B | |
| +0.35% | +3.20% | +14.40% | +81.76% | 56.37B | |
| +0.53% | +1.96% | +16.24% | +103.35% | 54.62B | |
| -2.81% | -4.31% | +23.50% | +47.83% | 44.06B | |
| -0.33% | -1.93% | +19.28% | +98.80% | 42.11B | |
| +0.55% | +2.31% | +225.14% | +866.21% | 41B | |
| +3.27% | +47.96% | +112.84% | +96.58% | 34.92B | |
| +1.22% | -1.44% | +14.57% | +46.95% | 32.82B | |
| +0.89% | +20.55% | -40.62% | +349.24% | 24.7B | |
| Average | +0.31% | +6.79% | +44.36% | +169.83% | 39.44B | |
| Weighted average by Cap. | +0.18% | +5.44% | +47.99% | +176.64% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 300K 402K 360K 331K 561K 38.16M 571K 3.95M 1.59M 20.07M 1.51M 1.48M 63.31M | 205K 275K 246K 226K 383K 26.08M 390K 2.7M 1.08M 13.72M 1.03M 1.01M 43.26M |
| Net income | - | - |
| Net Debt | -5.57M -7.46M -6.68M -6.14M -10.41M -708M -10.6M -73.27M -29.41M -373M -27.99M -27.4M -1.17B | -249K -333K -299K -275K -465K -31.65M -474K -3.27M -1.31M -16.65M -1.25M -1.22M -52.51M |
Employees
33
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-30 | GBX 82.50 | -.--% | 0 |
| 26-10-29 | GBX 82.50 | -.--% | 330 |
| 26-10-28 | GBX 82.50 | -.--% | 22,423 |
| 26-10-27 | GBX 82.50 | -.--% | 54 |
| 26-10-26 | GBX 82.50 | -.--% | 0 |
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.8250GBP
Average target price
2.505GBP
Spread / Average Target
+203.64%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- AREC Stock
Select your edition
All financial news and data tailored to specific country editions
